A breast cancer report often includes ER, PR, and HER2. These markers help the team understand features of the cancer and choose treatment approaches. They do not describe the person's worth, effort, or likelihood of coping with care.
The useful first step is to identify the final marker results and ask which decisions they affect. A single label does not provide the full treatment plan.
What ER and PR describe
ER stands for estrogen receptor, and PR stands for progesterone receptor. A receptor is a structure that can respond to a signal. When a breast cancer is hormone receptor-positive, hormone-related signaling can matter to its growth.
NCI explains breast cancer biomarker testing. Hormone receptor status helps determine whether endocrine, or hormone, therapy may be useful.
Ask whether the report gives a percentage or other detail that needs interpretation. Do not compare an isolated percentage with another person's treatment experience.
What HER2 describes
HER2 is a protein involved in cell growth. Testing can assess whether a cancer has increased HER2-related features. The result helps determine the role of treatments that target HER2.
Some results require additional testing or clarification. Modern treatment discussions can also include labels such as HER2-low, depending on the treatment setting and the complete report.
Ask the team whether the HER2 result is final, whether another test is pending, and which exact finding affects the proposed plan. A label alone should not be used to choose a medicine independently.
What triple-negative means
Triple-negative breast cancer is negative for estrogen and progesterone receptors and is not HER2-positive. It is a description of these test findings, not a statement that no treatment is available.
NCI's breast cancer types guide explains how biomarker features define some breast cancer subtypes. Other information, including stage, grade, and the person's health, remains important.
If the term is new to you, ask the clinician to explain which treatment options it makes relevant and which it makes less useful.
Keep different types of testing separate
A receptor test, a test estimating recurrence risk from tumor gene activity, and a test for inherited cancer risk answer different questions. Similar words such as “genetic” can cause confusion.
For each planned test, ask its purpose, which sample it uses, and which decision depends on it. Write the answer beside the test name.
If cancer returns or a new site is sampled, ask whether markers should be tested again. The team can explain whether the existing report is sufficient for the current decision.
Build a short report summary
Record the ER result, PR result, HER2 result, specimen date, and any pending addendum. Keep the original report because a specialist may need details beyond the summary.
At the results visit, ask:
- Are these the final results?
- Which treatments are relevant because of these findings?
- How do stage and grade affect the recommendation?
- Is additional tumor or inherited-risk testing appropriate?
- Who will explain any pending result?
An illustrative closing note is: “Markers are final; the team will discuss the treatment sequence after the remaining imaging.” That is more actionable than remembering only a subtype name.
Use these labels as an entry point to a care-team conversation. They are important pieces of information, but they become meaningful when connected to the full diagnosis and a specific treatment decision.
